Literature DB >> 15598035

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.

H Richly1, P Kupsch, K Passage, M Grubert, R A Hilger, R Voigtmann, B Schwartz, E Brendel, O Christensen, C G Haase, D Strumberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15598035     DOI： 10.5414/cpp42650

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  6 in total

1.  Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Authors:  David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John H Sampson; Jennifer Marcello; James E Herndon; Roger E McLendon; Dorothea Janney; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  J Neurooncol       Date:  2010-05-05       Impact factor: 4.130

Review 2.  New knowledge of the mechanisms of sorafenib resistance in liver cancer.

Authors:  Yan-Jing Zhu; Bo Zheng; Hong-Yang Wang; Lei Chen
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

3.  Current management of advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Fidel-David Huitzil-Melendez; Eileen M O'Reilly; Leonard B Saltz
Journal:  Gastrointest Cancer Res       Date:  2008-03

4.  Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.

Authors:  Erich Brendel; Matthias Ludwig; Chetan Lathia; Caroline Robert; Stanislas Ropert; Jean-Charles Soria; Jean-Pierre Armand
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-07       Impact factor: 3.333

Review 5.  Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

Authors:  Matteo Morotti; Prashanth Hari Dass; Adrian L Harris; Simon Lord
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

6.  Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Authors:  Shailender Bhatia; James Moon; Kim A Margolin; Jeffrey S Weber; Christopher D Lao; Megan Othus; Ana M Aparicio; Antoni Ribas; Vernon K Sondak
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.